MSCI (MSCI) Gets a Buy from Argus Research
In a report released on April 23, Kevin Heal from Argus Research maintained a Buy rating on MSCI, with a price target of $660.00. The company’s shares closed yesterday at $598.01.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Heal covers the Financial sector, focusing on stocks such as CME Group, Marketaxess Holdings, and UWM Holding. According to TipRanks, Heal has an average return of 11.6% and a 71.33% success rate on recommended stocks.
In addition to Argus Research, MSCI also received a Buy from Barclays’s Manav Patnaik in a report issued on April 22. However, on the same day, Wells Fargo assigned a Hold rating to MSCI (NYSE: MSCI).
Based on MSCI’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $850.8 million and a net profit of $406 million. In comparison, last year the company earned a revenue of $745.83 million and had a net profit of $288.6 million
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MSCI in relation to earlier this year. Most recently, in February 2026, Robert Ashe, a Director at MSCI bought 3,681.00 shares for a total of $1,999,556.01.
Read More on MSCI:
